Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average PT from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received an average recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $6.63.

A number of equities research analysts recently issued reports on the stock. JMP Securities reissued a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Canaccord Genuity Group lifted their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a report on Monday, January 6th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TSHA. Geode Capital Management LLC increased its position in Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after purchasing an additional 682,273 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at approximately $931,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Taysha Gene Therapies by 7.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after buying an additional 33,123 shares during the last quarter. Barclays PLC raised its position in shares of Taysha Gene Therapies by 356.0% during the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock valued at $513,000 after buying an additional 193,046 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in Taysha Gene Therapies in the second quarter valued at approximately $1,018,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock opened at $1.53 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock has a market capitalization of $313.56 million, a PE ratio of 2.43 and a beta of 0.95. The business has a 50 day simple moving average of $2.12 and a 200-day simple moving average of $2.10. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.